Drug assessment at a glance: A25-138[1]

Avapritinib (gastrointestinal stromal tumours)

20 July 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-138. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation
Intervention	avapritinib
Comparator	BSC
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available. Due to their study designs, the single-arm avapritinib studies NAVIGATOR and CS3007-101 did not allow for a comparison versus the comparator therapy.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Avapritinib (gastrointestinale Stromatumoren); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 06.05.2026]. URL: https://doi.org/10.60584/A25-138.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff zum Wirkstoff Avapritinib (Neubewertung Orphan > 30 Mio: Gastrointestinale Stromatumoren) [online]. 2026 [Accessed: 06.05.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1276/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-138.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de